Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Hepatocytes in the Drug Development Pipeline

Written by: | admin@medadnews.com | Dated: Tuesday, February 28th, 2017

 

Lonza to Host New Webinar: “Hepatocytes in the Drug Development Pipeline”

Cologne (DE) /Walkersville, MD (USA), 28 February 2017 – Lonza is hosting a free 60-minute webinar on 21 March 2017, titled “Hepatocytes in the Drug Development Pipeline.”

 

 

Due to significant differences in liver pathways across species, in vitro models of the human liver are increasingly being utilized to screen for the potential efficacy, metabolism and/or toxicity of candidate compounds. Cultures of primary human hepatocytes are widely considered to be the “gold standard” for creating such models.

 

Renowned researcher Dr. Salman Khetani from the Department of Bioengineering of the University of Illinois-Chicago (USA) will discuss the following topics during the webinar:

  • Tips and best practices for the short- and long-term culture of primary human hepatocytes
  • The utility of primary human hepatocytes cultures for assessing drug clearance, drug metabolite identification, and drug-transporter interactions, etc.

 

Anyone interested in attending the webinar can register by selecting the following link: https://attendee.gotowebinar.com/register/6087023194217314307 

 

Date: Tuesday, 21 March 2017, 9 AM PDT (Los Angeles) / 12 PM EDT (New York) / 4 PM GMT (London) / 5 PM CET (Berlin)

Speaker: Salman Khetani, Ph.D. Associate Professor, Bioengineering, University of Illinois-Chicago (USA)

 

 

Those unable to join the hepatocytes webinar are invited to visit the hepatocytes product page for further information. Alternatively, by registering interest in the webinar, participants will receive a link once it is available to view “on demand” via the Lonza website.

More information about Lonza’s upcoming webinars is available on the following website: www.lonza.com/researchwebinars

 

About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

 

Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

 

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

 

Lonza Contact Information

Lonza Cologne GmbH

Lonza Group Ltd

Lonza Group Ltd

Manager Marketing Communications

Head Corporate Communications

Head External Communications

Petra Haberkamm

Dominik Werner

Constance Ward

Tel +49 221 991990

Tel +41 61 316 8798

Tel +41 61 316 8840

Fax +49 221 99199498

Fax +41 61 316 9540

Fax +41 61 316 9840

marcom.lbs@lonza.com

dominik.werner@lonza.com

constance.ward@lonza.com

 

 

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

 

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2017 Focus: Payers, Biotech, HBA WOTY and more!

Subscribe

Ad Right Bottom

Main Navigation